Skip to Main content Skip to Navigation
Journal articles

Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients

Bertrand Lioger 1 Soujanya Ratna Edupuganti Denis Mulleman 2 Christophe Passot 2 Celine Desvignes 2 Theodora Bejan-Angoulvant 2 Gilles Thibault 2 Valérie Gouilleux-Gruart 3 Julien Mélet Gilles Paintaud 2 David Ternant 2
1 Service de Médecine Interne
2 GICC UMR 7292 CNRS - Génétique, immunothérapie, chimie et cancer (GICC), UMR 7292 CNRS [2012-2017]
3 Développement normal et pathologique des lymphocytes et signalisation
Abstract : Rituximab is a monoclonal antibody directed against CD20, which is approved in rheumatoid arthritis (RA). This study aimed at assessing the influence of CD19+ cell counts as target-antigen amount, and of immunoglobulin G (IgG) serum concentrations on rituximab pharmacokinetics in RA patients.
Keywords : rituximab elimination rate constant immunoglobulin pharmacokinetics rheumatoid arthritis
Document type :
Journal articles
Complete list of metadatas
https://hal-univ-tours.archives-ouvertes.fr/hal-02425330
Contributor : Valérie Gouilleux <>
Submitted on : Monday, December 30, 2019 - 12:18:22 PM
Last modification on : Friday, January 10, 2020 - 4:12:21 PM

Links full text

openaccess

Identifiers

Collections

UNIV-TOURS | CNRS

Citation

Bertrand Lioger, Soujanya Ratna Edupuganti, Denis Mulleman, Christophe Passot, Celine Desvignes, et al.. Antigenic burden and serum IgG concentrations influence rituximab pharmacokinetics in rheumatoid arthritis patients. British Journal of Clinical Pharmacology, Wiley, 2017, 83 (8), pp.1773-1781. ⟨10.1111/bcp.13270⟩. ⟨hal-02425330⟩

Export

BibTeX TEI DC DCterms EndNote

Share

Metrics

Record views

66